| Background：An enzyme linked immunosorbent assay (ELISA method) is used with an antibodyspecific for the antigen analyte and the enzyme reaction is connected, and produces a colorreaction by the enzyme with a substrate for the quantitative determination. Steps are asfollows:(1) the specific antibody and solid-phase carrier connected to form a solid phaseantibody.(2) add the subject specimen: time to react in contact with the solid-phaseantibody, antigen binding so the specimen with the antibody on the solid phase support toform a solid-phase antigen complexes.(3) adding labeled antibody: antigen-binding solidphase immune complexes on the enzyme-labeled antibody.(4) of substrate: compositesandwich enzymatic substrate becomes colored product. Qualitatively or quantitatively theantigen according to the degree of color reaction. The method has high specificity, and theoperation is simple, sensitive and reproducible advantages.2. Cerebral ischemic cerebrovascular disease is the most common form of it is due tosupply the brain artery thrombosis, causing arterial stenosis or occlusion, so the local bloodsupply to areas of ischemic brain tissue, neurological dysfunction and hypoxia, necrosiscaused. Commonly known as stroke, cerebral thrombosis because atherosclerotic plaqueswithin the brain blood vessels so that blood vessels narrow, rough surface, then plaquerupture, activate the body’s blood clotting system thrombosis, blood clotting plateletsrelease a variety of factors. Pathogenesis of acute cerebral thrombosis involves threefactors: the structural integrity of the vessel wall damage, bleeding, clotting, loss ofbalance and change the status of blood fibrinolytic system, the interaction of three factors,together constitute the basic conditions of thrombosis. In recent years, through in-depthstudy of the pathogenesis of thrombosis, the discovery process plays an important role inthe formation of many molecular markers of thrombosis, and also to reflect the above threefactors before thrombosis thrombotic state. And provide the basis for intervention at different stages of thrombosis.Objective:1. Establish of SGC ELISA method and to clinical testing.2. SGC, P-selectin, GP1bɑ implications for screening and diagnosis of patients withcerebral infarction.Method1. Selecting two monoclonal antibodies interfere with each other to builddouble-antibody sandwich, and the selection of the antibody-coated antibody AN51do, theelection marked SZ-2antibody, labeled with biotin SZ-2. AN51coated on a96-hole plate,then add infarction patient samples (including GC) is reacted with a solid phase support,and then add another biotin-labeled antibody SZ-2, and finally the oxidation reductionreaction with a substrate made of a color measured for35cases of cerebral infarction inpatients with OD values.2. GP1bɑ expressed SZ-2antibodies against GP1bɑ then flow cytometry35patientswith cerebral thrombosis and anti-P-selectin antibody with the SZ-51and then flowcytometry25patients with cerebral infarction P selectin expression.Results1. SGcELISA measurement range0.15-5.25ug/ml, sensitivity:50ug/l, Precision:The intra low, medium and high values of coefficients of variation were8.25%,7.35%and3.99%(n=6), approved Rooms were9.55%,8.82%and5.48%(n=6);accuracy: The average recovery was101.88%.35cases of cerebral infarction in SGCconcentration: normal SGC concentration of2.04±0.46was significantly lower than thatof patients with cerebral infarction SGC concentration;3.4±0.34ug/ml. The differencebetween the two groups was significant (P <0.05).2. Cerebral platelet CD62P (12.6±1.9%) was significantly higher percentage ofpositive (6.46±1.50%), cerebral blood platelet GP1bɑ (13.8±2.7)%positive percentagewas significantly lower than the control group (24.31±6.5%). The difference between thetwo groups was significant (P <0.05). Conclusion:1. Establish of SGC ELISA method and to clinical testing.2. SGC, P-selectin, GP1bɑ implications for screening and diagnosis of patients withcerebral infarction. |
PDF Full Text Request